Get started
GUFIC BIOSCIENCES LTD.GUFIC BIOSCIENCES LTD.GUFIC BIOSCIENCES LTD.

GUFIC BIOSCIENCES LTD.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

GUFICBIO trade ideas

YR 2022 Idea #150: Long on GUFICBIO This is a public swing trade idea and is only for Learning and observational purpose. Please understand your risk and take full responsibility of your actions. I might trail my stoploss after I get an entry but even if my original Stoploss hits, i exit the trade with pre-planned loss (risk). At target, I book usually 75% positions and trail stoploss for rest. Our objective to help anyone who wants to learn technical analysis using charts by demonstrating my real trade entries. You can post your queries in comment section here and we will try to answer them asap.
NSE:GUFICBIOLong
by onerighttrade
Buy Today, Sell Tomorrow: GUFICBIODON'T HAVE TIME TO MANAGE YOUR TRADES? - Take BTST trades at 3:25 pm every day - Book profits within the first 30 minutes of the market opening - Try to exit by taking 3-5% profit of each trade - SL can be taken when the 5/15 min candle closes below 44EMA - SL can also be maintained as 1% or closing below the low of the breakout candle The levels mentioned on the chart are calculated using the BREAKOUT INDICATOR Now, why do I prefer BTST over swing trades? The primary reason is that I have observed that 90% of the stocks give most of the movement in just 1-2 days and the rest of the time they either consolidate or fall Trendline Breakout in GUFICBIO Buy Today, Sell Tomorrow: GUFICBIO
NSE:GUFICBIOLong
by Kapil-Mittal
1
GUFICBIO chimoku Bullish Breakout Stock Name - Gufic Bio-Science. As per the ichimoiku rule, today's close is above the Conversion Line and future kumo is super bullish and chikou span is slanting upwards. All these parameters are showing bullishness. More strength will be visible once it will sustain above 290. Worth to keep in watch list for coming days. #This is not Buy and Sell recommendation to any one. This is for education purpose and a helping hand to learn trading in Market. # Rule Based Investing # Ichimoku Cloud # Ichimoku Followers I hope you all like my analysis. Please do share your thoughts into comment section of Trading View. Please give a like, it motivates me to do analysis and do share our channel with your friends as well.
NSE:GUFICBIOLong
by nikunjbhadja
Gufic breakout, pullback & bounce back 1. Buy or Sell at your own risk 2. Don't risk more than 1%-2% of your capital as stop loss 3. Position Size formula:- Stop Loss Amount/(Buy Price-Initial Stop Loss Price) 4. Sell on initial stop loss hit or daily RSI closing below 40 5. Some other ways to sell stocks can be a. 25% or 50% up in three weeks or less b. Weekly tailing tops with high volume c. Exhaustion gaps d. Heavy daily volume without further upside e. Largest one day price drop After consolidation since January 2022, NSE:GUFICBIO gave a break out of 12th April, went down below the support level and has given a bounce back today. Buy with a stop at ₹236. Other fundamentals: 1. The company has delivered good profit growth of 43.44% CAGR over last 5 years. 2. The company has a good return on equity (ROE) track record: 3 Years ROE 27.89%. 3. The company's median sales growth is 22.02% of last 10 year. 4. TTM sales growth of 71% and TTM profit growth of 160%. 5. Borrowings came down from ₹126cr on March 2020 to ₹35cr on September 2021. 6. Promoter holding increased from 65% in June 2021 to 75% in September 2021. 7. CRISIL Ratings has revised its outlook on the long-term bank facilities of Gufic Biosciences Limited (GBL) to 'Positive' from 'Stable', while reaffirming the rating at 'CRISIL BBB+'. and has assigned its 'CRISIL A2' rating to the short-term bank facility. The outlook revision reflects improvement in GBL’s business risk profile in fiscal 2022, marked by expected revenue of Rs. 750 crore, increase from Rs 488 crores in fiscal 2021, driven by capacity expansion and higher revenue from critical drugs. Operating profitability improved in fiscal 2021 to 17.6% and expected to sustain in fiscal 2022. With further capacity expansion in FY2023, revenue is expected to grow in future years. Hence, sustenance of operating margin and revenue growth will remain key rating sensitivity factors. Financial profile and liquidity continue to be strong. 8. GBL obtained various certifications and approvals for its manufacturing facilities and diversified its product portfolio through continuous research and development. The top 10 products contributed to 34% of revenue till the third quarter of fiscal 2022. Revenue grew to an estimated Rs 750 crore in fiscal 2022 from Rs 300 crore in fiscal 2018. 9. Financial risk should remain strong despite the huge, debt-funded capex to be undertaken in fiscal 2023. Networth was Rs 173 crore as on March 31, 2021 and is estimated at Rs 250 crore on March 31, 2022. Its controlled reliance on external debt has led to comfortable gearing and total outside liabilities to adjusted networth (TOLANW) ratios, which are estimated to be 0.14-0.15 times and 0.8-0.9 times, respectively in fiscal 2022. Debt protection metrics are robust, with interest coverage and net cash accrual to adjusted debt ratios estimated at 25 times and 2.5 times, respectively, for fiscal 2022.
NSE:GUFICBIOLong
by akashbothra